



## JOINT WORKING EXECUTIVE SUMMARY

**Project Title:** Development of a costed pathway for early and advanced breast cancer and simulation model at Clatterbridge Cancer Centre.

### **Project description:**

The aim of the project is to develop a costed breast cancer pathway and simulation model that will inform redesign of services as part of the transformation of cancer services taking place in Cheshire and Merseyside locality.

### **Organisations involved:**

The Clatterbridge Cancer Centre NHS Foundation Trust and Roche Products Ltd.

### **Project approach:**

This project will map and identify costs associated with the breast cancer pathway (including referral, diagnostic and treatment) as part of a hub and spoke breast cancer service model working with Clatterbridge Cancer Centre. The project will be of value to both providers and those that commission care. Project outputs can be used to optimise the breast cancer pathway and simulate service redesign proposals that will enable more effective resource allocation to improve service quality and patient experience.

### **Expected outcomes:**

#### **Benefits to Patients:**

Improvement in equity of access and quality of services such as reduced waiting times via use of costed pathway and simulation model to identify potential areas for service improvement and redesign.

#### **Benefit to NHS:**

Understanding of their current breast cancer service to inform redesign of services as part of the transformation program taking place. Costed pathway modelling will help support commissioning and optimisation of the breast cancer pathway to improve patient care.

#### **Benefits to Roche:**

The project will provide a system-level understanding supporting work to ensure that breast cancer continues to be appropriately commissioned with adequate funding and infrastructure for current and new interventions as they become available. The simulation tool could be used to share best practice across other NHS sites.

Roche Products Ltd manufacture three of the licensed treatment choices for breast cancer patients. Treatment choices will not be modified as part of this joint working project as the project is to support redesign of services to improve patient care and experience. Improved referral and diagnosis may alter treatment rates but this is not being measured as part of this project.

## **Resource Breakdown**

Roche Products Ltd contribution to the Joint working project is £37,000 to support consultancy costs in pathway mapping ,building of the simulation model and to support publication.

The Clatterbridge Cancer Centre NHS Foundation Trust estimated contribution to the project is £38,000, based on prorated personnel resource equivalent as part of the steering committee and other NHS personnel input into the project.

This document has been produced by Roche Products Ltd.